ASX Announcements

The company’s latest announcements on the Australian Stock Exchange.

News Articles

Media Features

Industry Coverage

Document Name

Date

Link

Investor Presentation – Stabl-Im program

25 June, 2026

View ASX Announcement

Change of Registered Office Address

26 May, 2026

View ASX Announcement

CRO Engaged to Advance Stabl-Im Phase 1 Trial

22 May, 2026

View ASX Announcement

March 2026 Quarterly Activities Report and Appendix 4C

30 April, 2026

View ASX Announcement

Dr Danielle Meyrick appointed as CEO

28 April 2026 11:29pm

View ASX Announcement

Key management changes

4 March, 2026

View ASX Announcement

Appendix 4D & Half-Year Financial Report to 31 December 2025

24 February, 2026

View ASX Announcement

December 2025 Quarterly Activities Report and Appendix 4C

29 January, 2026

View ASX Announcement

Final Director’s Interest Notice – John Mathias

1 January, 2026

View ASX Announcement
Document namedateLink
Becoming a substantial holder – Daniel Tillett22 December 2025 10:27pmView ASX Announcement
Second-tranche placement funding completed22 December 2025 8.24amView ASX Announcement
Cleansing Notice19 December 2025 5.54amView ASX Announcement
Positive results from US-veteran mental health trial18 December 2025 5.23amView ASX Announcement
Results of General Meeting12 December 2025 10.47amView ASX Announcement
Resignation of Director – John Mathias5 December 2025 8.15amView ASX Announcement
Cleansing Notice2 December 2025 3.16pmView ASX Announcement
Results of Annual General Meeting21 November 2025 9.24amView ASX Announcement
Notice of General Meeting & Proxy Form & Access Letter12 November 2025 7.33amView ASX Announcement
TRI Exercises Option to Advance Acquisition of Stabl-Im5 November 2025 5.48amView ASX Announcement
September 2025 Quarterly Activities Report and Appendix 4C31 October 2025 5.37amView ASX Announcement
Change in substantial holding – FIL Limited and associates30 October 2025 6.12amView ASX Announcement
Cleansing Notice27 October 2025 6.17amView ASX Announcement
Letter to Shareholders & Notice of AGM & Proxy Form22 October 2025 9.35amView ASX Announcement
US-veteran mental health trial patient recruitment complete22 October 2025 5.30amView ASX Announcement
Acquisition of Stabl-Im technology and Private Placement16 October 2025 6.26amView ASX Announcement
Extension of Trading Suspension13 October 2025 5.55amView ASX Announcement
Positive interim results from US-veteran focused trial8 October 2025 6.25amView ASX Announcement
Corporate Governance Statement29 September 2025 9.11amView ASX Announcement
Appendix 4G29 September 2025 9.10amView ASX Announcement
2025 Annual Report29 September 2025 9.09amView ASX Announcement
Notice of AGM and Closing Date for Director Nominations25 September 2025 2.24pmView ASX Announcement
Appendix 4E – Preliminary Final Report29 August 2025 6.12amView ASX Announcement
30 patients enrolled in innovative mental health trial25 August 2025 6.18amView ASX Announcement
June 2025 Quarterly Activities Report and Appendix 4C31 July 2025 7.10amView ASX Announcement
Update on recruitment for mental health trial in veterans17 July 2025 6.27amView ASX Announcement
First patient recruited in innovative mental health trial19 June 2025 6.22amView ASX Announcement
Cleansing Notice11 June 2025 6.22amView ASX Announcement
Site activation for trial at West LA VA Medical Center30 May 2025 6.23amView ASX Announcement
Cleansing Notice20 May 2025 7.46amView ASX Announcement
Results of General Meeting13 May 2025 9.22amView ASX Announcement
Pilot Agreement with Major League Baseball affiliated Academy7 May 2025 6.21amView ASX Announcement
March 2025 Quarterly Activities Report and Appendix 4C30 April 2025 9.29amView ASX Announcement
IRB approval for trial with US Dept of Veterans Affairs28 April 2025 6.31amView ASX Announcement
Letter to Shareholders & Notice of GM & Proxy Form3 April 2025 8.14amView ASX Announcement
Cleansing Notice26 March 2025 7.16amView ASX Announcement
Cleansing Notice24 March 2025 7.23amView ASX Announcement
TrivarX Receives Firm Commitments to Raise $2.25 million17 March 2025 6.25amView ASX Announcement
Trial with US Department of Veterans Affairs13 March 2025 5.34amView ASX Announcement
Appendix 4D & Half-Year Financial Report to 31 December 202428 February 2025 12.11amView ASX Announcement
December 2024 Quarterly Activities Report and Appendix 4C31 January 2025 8.20amView ASX Announcement
Positive engagement with FDA following pre-submission meeting for MEB-00128 January 2025 9.42amView ASX Announcement
Cleansing Notice14 January 2025 2.14pmView ASX Announcement
Document namedateLink
TrivarX Receives $1.03m R&D Tax Incentive6 Dec 2024 8.20amView ASX Announcement
Change of Director’s Interest Notice – Chris Ntoumenopoulos5 Dec 2024 9.42amView ASX Announcement
Change of Director’s Interest Notice – David Trimboli5 Dec 2024 9.42amView ASX Announcement
Change of Director’s Interest Notice – Tony Keating5 Dec 2024 9.40amView ASX Announcement
Cleansing Notice5 Dec 2024 8.36amView ASX Announcement
Notification regarding unquoted securities – TRI5 Dec 2024 8.35amView ASX Announcement
Application for quotation of securities – TRI4 Dec 2024 5.34pmView ASX Announcement
Results of Annual General Meeting28 Nov 2024 12.22pmView ASX Announcement
Annual General Meeting – Chairman Update28 Nov 2024 8.21amView ASX Announcement
New AI Tool Expands Patient Reach and Market Opportunities7 Nov 2024 8.22amView ASX Announcement
September 2024 Quarterly Activities Report and Appendix 4C30 Oct 2024 2.13pmView ASX Announcement
Proposed issue of securities – TRI28 Oct 2024 12.00pmView ASX Announcement
Letter to Shareholders & Notice of AGM & Proxy Form28 Oct 2024 10.49amView ASX Announcement
Notice of AGM and Closing Date for Director Nominations9 Oct 2024 8.29amView ASX Announcement
Initial Director’s Interest Notice – John Mathias7 Oct 2024 8.41amView ASX Announcement
Company Secures R&D Loan Facility1 Oct 2024 8.26amView ASX Announcement
TrivarX Appoints Leading US Healthcare Executive to Board25 Sep 2024 8.25amView ASX Announcement
TrivarX Requests Pre-Submission Meeting with US FDA24 Sep 2024
8:23am		View ASX Announcement
Appendix 4G19 Sep 2024
8:27am		View ASX Announcement
Corporate Governance Statement19 Sep 2024
8:27am		View ASX Announcement
2024 Annual Report19 Sep 2024
8:27am		View ASX Announcement
Notification under Listing Rule 4.3D19 Sep 2024
8:22am		View ASX Announcement
Appendix 4E – Preliminary Final Report29 Aug 2024
9:08am		View ASX Announcement
Notification of cessation of securities – TRI20 Aug 2024
9:16am		View ASX Announcement
June 2024 Quarterly Activities Report and Appendix 4C31 Jul 2024
1:49pm		View ASX Announcement
Initial Director’s Interest Notice – Tony Keating30 Jul 2024
9:27am		View ASX Announcement
Final Director’s Interest Notice – Tom Young30 Jul 2024
9:26am		View ASX Announcement
TechKnow Invest Roadshow presentation and livestream links30 Jul 2024
9:22am		View ASX Announcement
Positive Results from Phase 2 SAMDE Study30 Jul 2024
9:07am		View ASX Announcement
Trading Halt29 Jul 2024
8:46am		View ASX Announcement
Appointment of Dr Tony Keating & Resignation of Dr Tom Young29 Jul 2024
2:22pm		View ASX Announcement
Change in substantial holding12 Jul 2024
2:22pm		View ASX Announcement
Change of Director’s Interest Notice – David Trimboli10 Jul 2024 8:00amView ASX Announcement
Change of Director’s Interest Notice – Chris Ntoumenopoulos10 Jul 2024 8:00amView ASX Announcement
Cleansing Notice10 Jul 2024 7:55amView ASX Announcement
Application for quotation of securities – TRI10 Jul 2024 7:49amView ASX Announcement
Application for quotation of securities – TRI10 Jul 2024 7:45amView ASX Announcement
Notification regarding unquoted securities – TRI10 Jul 2024 7:45amView ASX Announcement
Notification regarding unquoted securities – TRI10 Jul 2024 7:40amView ASX Announcement
Application for quotation of securities – TRI10 Jul 2024 7:27amView ASX Announcement
Completion of Phase 2 SAMDE Trial10 Jul 2024 6:25amView ASX Announcement
Proposed issue of securities – TRI9 Jul 2024 12:34pmView ASX Announcement
Results of General Meeting5 Jul 2024 9:24amView ASX Announcement
TrivarX SAMDE Trial Update20 Jun 2024 6:24amView ASX Announcement
Update – Proposed issue of securities – TRI11 Jun 2024 7:10amView ASX Announcement
Proposed issue of securities – TRI4 Jun 2024 8:48amView ASX Announcement
Letter to Shareholders & Notice of GM & Proxy Form4 Jun 2024 8:33amView ASX Announcement
Presentation – Investor Webinar22 May 2024 7:57amView ASX Announcement
Investor Webinar22 May 2024 7:54amView ASX Announcement
Notification regarding unquoted securities – TRI16 May 2024 7:51amView ASX Announcement
Change in substantial holding14 May 2024 10:15amView ASX Announcement
Cleansing Notice10 May 2024 8:03amView ASX Announcement
Application for quotation of securities – TRI10 May 2024 8:01amView ASX Announcement
Notification regarding unquoted securities – TRI10 May 2024 7:55amView ASX Announcement
Application for quotation of securities – TRI10 May 2024 7:49amView ASX Announcement
Application for quotation of securities – TRI10 May 2024 7:46amView ASX Announcement
Proposed issue of securities – TRI10 May 2024 6:21amView ASX Announcement
Proposed issue of securities – TRI2 May 2024 6:50amView ASX Announcement
Proposed issue of securities – TRI2 May 2024 6:49amView ASX Announcement
TrivarX Receives Firm Commitments to Raise $2.5 million2 May 2024 6:49amView ASX Announcement
Trading Halt30 Apr 20246:48amView ASX Announcement
March 2024 Quarterly Activities Report and Appendix 4C29 Apr 2024 2:56pmView ASX Announcement
Cleansing Notice26 Mar 2024 5:46amView ASX Announcement
Application for quotation of securities – TRI26 Mar 2024 5:44amView ASX Announcement
Cleansing Notice1 Mar 2024 7:06amView ASX Announcement
Application for quotation of securities – TRI1 Mar 2024 7:04amView ASX Announcement
Appendix 4D & Half-Year Financial Report to 31 December 202328 Feb 2024 3:06pmView ASX Announcement
Positive Engagement Meeting with US FDA for MEB-00128 Feb 2024 :38amView ASX Announcement
Response to ASX Price Query22 Feb 2024 10:08amView ASX Announcement
Cleansing Notice15 Feb 2024 5:22amView ASX Announcement
Application for quotation of securities – TRI15 Feb 2024 5:20amView ASX Announcement
Research Collaboration with Northern Michigan University9 Feb 2024 5:22amView ASX Announcement
TrivarX Receives $888k R&D Tax Incentive8 Feb 2024 5:37amView ASX Announcement
TRI-001 Algorithm and Phase 2 Trial Update5 Feb 2024 5:27amView ASX Announcement
December 2023 Quarterly Activities Report and Appendix 4C31 Jan 2024 8:42amView ASX Announcement
Notification of cessation of securities – TRI opens new window31 Jan 2024 8:42amView ASX Announcement
Document namedateLink
Notification of cessation of securities – TRI21 Dec 2023 7:51amView ASX Announcement</a
Cleansing Notice19 Dec 2023 5:18amView ASX Announcement</a
Application for quotation of securities – TRI19 Dec 2023 5:18amView ASX Announcement</a
Proposed issue of securities – TRI18 Dec 2023 6:36amView ASX Announcement</a
Change of Share Registry Details12 Dec 2023 10:43amView ASX Announcement</a
Results of Annual General Meeting29 Nov 2023 9:16amView ASX Announcement</a
Cleansing Notice20 Nov 2023 6:10amView ASX Announcement</a
Application for quotation of securities – TRI20 Nov 2023 6:07amView ASX Announcement</a
Phase 2 SAMDE Study Update20 Nov 2023 5:36amView ASX Announcement</a
Proposed issue of securities – TRI16 Nov 2023 10:26amView ASX Announcement</a
Investor Presentation – November 202316 Nov 2023 6:07amView ASX Announcement</a
Cleansing Notice15 Nov 2023 6:04amView ASX Announcement</a
Application for quotation of securities – TRI15 Nov 2023 5:55amView ASX Announcement</a
Option Terms and Conditions14 Nov 2023 7:54amView ASX Announcement</a
Proposed issue of securities – TRI14 Nov 2023 7:44amView ASX Announcement</a
Proposed issue of securities – TRI14 Nov 2023 7:40amView ASX Announcement</a
Letter to Shareholders & Notice of AGM & Proxy FormOctober 2023View ASX Announcement</a
September 2023 Quarterly Activities Report and Appendix 4COctober 2023View ASX Announcement</a
Completion of Consolidation CapitalOctober 2023View ASX Announcement</a
Consolidation/Split – TRIOctober 2023View ASX Announcement</a
Change in substantial holdingOctober 2023View ASX Announcement</a
Change of Director’s Interest Notice – David TrimboliOctober 2023View ASX Announcement</a
Change of Director’s Interest Notice – Chris NtoumenopolosOctober 2023View ASX Announcement</a
Notification regarding unquoted securities – MEBOctober 2023View ASX Announcement</a
Cleansing NoticeOctober 2023View ASX Announcement</a
Results of General MeetingOctober 2023View ASX Announcement</a
Board and Management TransitionOctober 2023View ASX Announcement</a
Application for quotation of securities – MEBOctober 2023View ASX Announcement</a
Change of Company Name ASX CodeOctober 2023View ASX Announcement</a
Notification of cessation of securities – MEBOctober 2023View ASX Announcement</a
Notice of AGM and Closing Date for Director NominationsOctober 2023View ASX Announcement</a
Appendix 4GSeptember 2023View ASX Announcement</a
Corporate Governance StatementSeptember 2023View ASX Announcement</a
2023 Annual ReportSeptember 2023View ASX Announcement</a
Proposed issue of securities – MEBSeptember 2023View ASX Announcement</a
Letter to Shareholders & Notice of GM & Proxy FormSeptember 2023View ASX Announcement</a
Phase 2 Trial Commences for SAMDE StudySeptember 2023View ASX Announcement</a
Appendix 4E – Preliminary Final ReportAugust 2023View ASX Announcement</a
Notification of cessation of securities – MEBAugust 2023View ASX Announcement</a
Change in substantial holdingAugust 2023View ASX Announcement</a
Cleansing NoticeAugust 2023View ASX Announcement</a
Application for quotation of securities – MEBAugust 2023View ASX Announcement</a
Proposed issue of securities – MEBAugust 2023View ASX Announcement</a
Medibio Receives Firm Commitments to Raise $2.25mAugust 2023View ASX Announcement</a
Trading HaltAugust 2023View ASX Announcement</a
June 2023 Quarterly Activities Report and Appendix 4CJuly 2023View ASX Announcement</a
Phase 1 Trial Completed for SAMDE StudyJuly 2023View ASX Announcement</a
Update on Breakthrough Device Designation with US FDAJuly 2023View ASX Announcement</a
Notification regarding unquoted securities – MEBJuly 2023View ASX Announcement</a
Notification regarding unquoted securities – MEBJuly 2023View ASX Announcement</a
Notification regarding unquoted securities – MEBJuly 2023View ASX Announcement</a
Application for quotation of securities – MEBJuly 2023View ASX Announcement</a
Change of Director’s Interest Notice – David TrimboliJune 2023View ASX Announcement</a
Change of Director’s Interest Notice – Chris NtoumenopoulosJune 2023View ASX Announcement</a
Notification regarding unquoted securities – MEBJune 2023View ASX Announcement</a
Application for quotation of securities – MEBJune 2023View ASX Announcement</a
Notification of cessation of securities – MEBJune 2023View ASX Announcement</a
Notification regarding unquoted securities – MEBMay 2023View ASX Announcement</a
Application for quotation of securities – MEBMay 2023View ASX Announcement</a
Medibio Completes Share Purchase PlanMay 2023View ASX Announcement</a
Results of Extraordinary General MeetingMay 2023View ASX Announcement</a
Investor Presentation – May 2023May 2023View ASX Announcement</a
Change in Venue and Time for Extraordinary General MeetingMay 2023View ASX Announcement</a
March 2023 Quarterly Activities Report and Appendix 4CApril 2023View ASX Announcement</a
Letter to Shareholders & Notice of EGM & Proxy FormApril 2023View ASX Announcement</a
MEB Executes Bridging Loans with DirectorsApril 2023View ASX Announcement</a
Initial Director’s Interest Notice – Thomas YoungApril 2023View ASX Announcement</a
Share Purchase Plan Supplementary ProspectusApril 2023View ASX Announcement</a
Final Director’s Interest NoticeApril 2023View ASX Announcement</a
Board & Managment Changes & Change of OfficesApril 2023View ASX Announcement</a
Update on Share Purchase Plan TimetableApril 2023View ASX Announcement</a
Appendix 3ZMarch 2023View ASX Announcement</a
Resignation of Non-Executive DirectorMarch 2023View ASX Announcement</a
Share Purchase Plan ProspectusMarch 2023View ASX Announcement</a
Medibio Lodges Breakthrough Device Designation with FDAFebruary 2023View ASX Announcement</a
Update to Share Purchase Plan TimetableFebruary 2023View ASX Announcement</a
Half Yearly Report and AccountsFebruary 2023View ASX Announcement</a
Change in substantial holdingFebruary 2023View ASX Announcement</a
708A Cleansing NoticeFebruary 2023View ASX Announcement</a
Application for quotation of securities – MEBFebruary 2023View ASX Announcement</a
Update to Share Purchase Plan TimetableFebruary 2023View ASX Announcement</a
Appendix 3XFebruary 2023View ASX Announcement</a
Proposed issue of securities – MEBFebruary 2023View ASX Announcement</a
MEB to Raise up to $2.75 million By Way of a Placement & SPPFebruary 2023View ASX Announcement</a
Medibio Appoints Non-Executive Director to the BoardFebruary 2023View ASX Announcement</a
Trading HaltFebruary 2023View ASX Announcement</a
Medibio Quarterly Update and Cashflow ReportFebruary 2023View ASX Announcement</a
Notification of cessation of securities – MEBFebruary 2023View ASX Announcement</a
Appendix 3ZFebruary 2023View ASX Announcement</a
Document namedateLink
Medibio Receives R&D Tax Incentive RefundNovember 2022View ASX Announcement</a
Results of Annual General MeetingNovember 2022View ASX Announcement</a
CEO Presentation to 2022 AGMNovember 2022View ASX Announcement</a
Chair’s Address to the 2022 Annual General MeetingNovember 2022View ASX Announcement</a
Resignation of Director and Resolution WithdrawalNovember 2022View ASX Announcement</a
Medibio Quarterly Update and Cashflow ReportOctober 2022View ASX Announcement</a
Medibio Announces Appointment of Non-Executive ChairOctober 2022View ASX Announcement</a
Notice of Annual General Meeting/Proxy FormOctober 2022View ASX Announcement</a
Appendix 4G and Corporate Governance StatementSeptember 2022View ASX Announcement</a
2022 Annual ReportSeptember 2022View ASX Announcement</a
Director Nomination Closing Date for AGMSeptember 2022View ASX Announcement</a
Medibio Appoints CEOSeptember 2022View ASX Announcement</a
Initial Directors Interest NoticeSeptember 2022View ASX Announcement</a
Appendix 4E and Preliminary Final ReportAugust 2022View ASX Announcement</a
708A Cleansing NoticeAugust 2022View ASX Announcement</a
Notification regarding unquoted securities – MEBAugust 2022View ASX Announcement</a
Notification regarding unquoted securities – MEBAugust 2022View ASX Announcement</a
Non-Executive Director AppointmentAugust 2022View ASX Announcement</a
Results of General MeetingJuly 2022View ASX Announcement</a
Medibio Quarterly Update and Cashflow ReportJuly 2022View ASX Announcement</a
Sleep Analysis Depressive Burden Study Clinical TrialJuly 2022View ASX Announcement</a
Update – Proposed issue of securities – MEBJuly 2022View ASX Announcement</a
Notice of Extraordinary General Meeting/Proxy FormJuly 2022View ASX Announcement</a
Notification of cessation of securities – MEBJuly 2022View ASX Announcement</a
Notification of cessation of securities – MEBJuly 2022View ASX Announcement</a
Change in substantial holdingJuly 2022View ASX Announcement</a
708A Cleansing NoticeJune 2022View ASX Announcement</a
Application for quotation of securities – MEBJune 2022View ASX Announcement</a
Appendix 3ZJune 2022View ASX Announcement</a
Proposed issue of securities – MEBJune 2022View ASX Announcement</a
MEB to Raise $1.4m by way of a Placement & MD/CEO ResignsJune 2022View ASX Announcement</a
Reinstatement to QuotationJune 2022View ASX Announcement</a
Update on Voluntary SuspensionJune 2022View ASX Announcement</a
Voluntary SuspensionJune 2022View ASX Announcement</a
Appendix 3ZJune 2022View ASX Announcement</a
FDA Confirm Diagnostic Method on Depression Validation TrialJune 2022View ASX Announcement</a
708A Cleansing NoticeJune 2022View ASX Announcement</a
Application for quotation of securities – MEBJune 2022View ASX Announcement</a
Trading HaltMay 2022View ASX Announcement</a
Non-Executive Director Moves to Advisory BoardMay 2022View ASX Announcement</a
Medibio Quarterly Update and Cashflow ReportApril 2022View ASX Announcement</a
Medibio to Host Live Corporate Webinar on March 25March 2022View ASX Announcement</a
Application for quotation of securities – MEBMarch 2022View ASX Announcement</a
Change in substantial holdingMarch 2022View ASX Announcement</a
Initial Director’s Interest NoticeMarch 2022View ASX Announcement</a
Entitlement Offer Shareholder Withdrawal RightsMarch 2022View ASX Announcement</a
Investor Presentation March 2022March 2022View ASX Announcement</a
Non-Executive Director AppointmentMarch 2022View ASX Announcement</a
Termination of Underwriting AgreementMarch 2022View ASX Announcement</a
Half Yearly Report and AccountsFebruary 2022View ASX Announcement</a
Application for quotation of securities – MEBFebruary 2022View ASX Announcement</a
708A Cleansing NoticeFebruary 2022View ASX Announcement</a
Appendix 3XFebruary 2022View ASX Announcement</a
Non-Executive Director AppointmentFebruary 2022View ASX Announcement</a
Update – Proposed issue of securities – MEBFebruary 2022View ASX Announcement</a
MEB Announces Extension to Entitlement OfferFebruary 2022View ASX Announcement</a
Results of Extraordinary General MeetingFebruary 2022View ASX Announcement</a
Medibio Quarterly Update and Cashflow ReportJanuary 2022View ASX Announcement</a
Despatch of Offer Letter to Eligible ShareholdersJanuary 2022View ASX Announcement</a
Letter to Ineligible Shareholders – Entitlement OfferJanuary 2022View ASX Announcement</a
Letter to Option holders – Entitlement OfferJanuary 2022View ASX Announcement</a
Update – Proposed issue of securities – MEBJanuary 2022View ASX Announcement</a
Entitlement Offer DocumentJanuary 2022View ASX Announcement</a
Section 708AA(2)(F) Cleansing Notice – Entitlement OfferJanuary 2022View ASX Announcement</a
Non-Renounceable Entitlement Offer Underwriting UpdateJanuary 2022View ASX Announcement</a
Notification regarding unquoted securities – MEBJanuary 2022View ASX Announcement</a
Update – Proposed issue of securities – MEBJanuary 2022View ASX Announcement</a
Notification of cessation of securities – MEBJanuary 2022View ASX Announcement</a
Update to Entitlement Offer TimetableJanuary 2022View ASX Announcement</a
Document namedateLink
Notice of Extraordinary General Meeting/Proxy FormDecember 2021View ASX Announcement</a
Section 708A Cleansing NoticeDecember 2021View ASX Announcement</a
Application for quotation of securities – MEBDecember 2021View ASX Announcement</a
Section 708A Cleansing NoticeDecember 2021View ASX Announcement</a
MEB to Raise up to $5.7 million by way of a Placement & NREODecember 2021View ASX Announcement</a
Proposed issue of securities – MEBDecember 2021View ASX Announcement</a
Investor Presentation December 2021December 2021View ASX Announcement</a
Trading HaltDecember 2021View ASX Announcement</a
Appendix 3YDecember 2021View ASX Announcement</a
Application for quotation of securities – MEBDecember 2021View ASX Announcement</a
Results of Annual General MeetingNovember 2021View ASX Announcement</a
Chairman’s Address to the 2021 Annual General MeetingNovember 2021View ASX Announcement</a
JobKeeper Payments NoticeNovember 2021View ASX Announcement</a
Medibio Quarterly Update and Cashflow ReportOctober 2021View ASX Announcement</a
Medibio Quarterly Update and Cashflow ReportOctober 2021View ASX Announcement</a
Expiry of MEBOB Quoted OptionsOctober 2021View ASX Announcement</a
Proposed issue of securitiesOctober 2021View ASX Announcement</a
Notice of Annual General Meeting / Proxy FormOctober 2021View ASX Announcement</a
LUCA Launches TodayOctober 2021View ASX Announcement</a
FDA Strategy and Regulatory UpdateSeptember 2021View ASX Announcement</a
Appointment of Dr Elizabeth Lombardo to Advisory BoardSeptember 2021View ASX Announcement</a
CEO/MD Remuneration Update and Company Secretary ResignationSeptember 2021View ASX Announcement</a
Appendix 4G and Corporate Governance StatementAugust 2021View ASX Announcement</a
Appendix 4E and Annual ReportAugust 2021View ASX Announcement</a
Medibio Quarterly Update and Cashflow ReportJune 2021View ASX Announcement</a
MEB Appoints R&CPMK as Communications Agency in the USJune 2021View ASX Announcement</a
Newsletter to ShareholdersJune 2021View ASX Announcement</a
Section 708A Cleansing Notice and Appendix 2AJune 2021View ASX Announcement</a
Medibio strengthens its IP protectionMay 2021View ASX Announcement</a
Medibio Quarterly Update and Cashflow ReportMay 2021View ASX Announcement</a
Re-submission of FDA 510(k) applicationApril 2021View ASX Announcement</a
Consumer Mental Health App Development – Second Test PhaseApril 2021View ASX Announcement</a
Appendix 3GApril 2021View ASX Announcement</a
Section 708A Cleansing Notice and Appendix 2AApril 2021View ASX Announcement</a
Appendix 2AApril 2021View ASX Announcement</a
Proposed issue of Securities – MEB (Revised)April 2021View ASX Announcement</a
MEB Share Purchase Plan Closes Strongly OversubscribedApril 2021View ASX Announcement</a
Supplementary ProspectusApril 2021View ASX Announcement</a
Results of General MeetingMarch 2021View ASX Announcement</a
Annual General MeetingMarch 2021View ASX Announcement</a
Medibio Begins Implementation of ilumen in the United KingdomMarch 2021View ASX Announcement</a
Medibio To Present at World Forum for Sleep MedicineMarch 2021View ASX Announcement</a
Share Purchase Plan ProspectusMarch 2021View ASX Announcement</a
Half Yearly Report and AccountsFebruary 2021View ASX Announcement</a
Notice of General Meeting/Proxy FormFebruary 2021View ASX Announcement</a
Notice of Change of Interests of Substantial HolderFebruary 2021View ASX Announcement</a
Appendix 3G Notification of issue, conversion or payment of Equity + SecuritiesFebruary 2021View ASX Announcement</a
Section 708A Cleansing Notice Appendix 2AFebruary 2021View ASX Announcement</a
Appendix 3GFebruary 2021View ASX Announcement</a
Appendix 3B Proposed issue of + securitiesFebruary 2021View ASX Announcement</a
Underwritten Share Purchase Plan UpdateFebruary 2021View ASX Announcement</a
Investors Presentation FEB 2021February 2021View ASX Announcement</a
Appendix 3B Proposed issue of +securitiesFebruary 2021View ASX Announcement</a
Proposed issue of securities – Announcement Summary 2February 2021View ASX Announcement</a
Medibio to Raise up to $3.5 million By Way of a Placement and SPPFebruary 2021View ASX Announcement</a
Proposed issue of securities – Announcement SummaryFebruary 2021View ASX Announcement</a
ASX- MEB Trading HaltFebruary 2021View ASX Announcement</a
December 2020 Quarterly Activities Report and Appendix 4CFebruary 2021View ASX Announcement</a
Medibio Granted CE Mark Approval for MEBsleepJanuary 2021View ASX Announcement</a
US FDA advises further data needed for MEBsleep approvalJanuary 2021View ASX Announcement</a
Medibio’s Patent-Protected Consumer Mental Health App, Commences Initial Testing PhaseJanuary 2021View ASX Announcement</a
Document namedateLink
Updated Capital StructureDecember 2020View ASX Announcement
Appendix 3Y Change of Director’s Interest NoticeDecember 2020View ASX Announcement
Appendix 3G Notification of issue, conversion or payment up of equity + securitiesDecember 2020View ASX Announcement
Release of Securities from EscrowDecember 2020View ASX Announcement
Medibio signs Global Master License and Services Agreement with Compass Group Plc. for ilumenDecember 2020View ASX Announcement
Medibio Investor Webinar PresentationDecember 2020View ASX Announcement
Update on Breakthrough Device ProgramDecember 2020View ASX Announcement
Results of Annual General MeetingNovember 2020View ASX Announcement
Medibio Investor Webinar PresentationNovember 2020View ASX Announcement
Chairman’s Address Annual General MeetingNovember 2020View ASX Announcement
Amended ConstitutionNovember 2020View ASX Announcement
MEB AGM PresentationNovember 2020View ASX Announcement
Chairman’s Address Annual General MeetingNovember 2020View ASX Announcement
Medibio Investor Webinar PresentationNovember 2020View ASX Announcement
Chairman’s Address Annual General MeetingNovember 2020View ASX Announcement
Amended ConstitutionNovember 2020View ASX Announcement
MEB AGM PresentationNovember 2020View ASX Announcement
Notice of Annual General MeetingNovember 2020View ASX Announcement
Medibio Signs Clinical Trial Agreement With US-based MedBridge Healthcare LLC For its Depressive Burden TrialOctober 2020View ASX Announcement
Medibio Submits Request For FDA Breakthrough Device DesignationOctober 2020View ASX Announcement
Appendix 3GOctober 2020View ASX Announcement
Securities Trading PolicyOctober 2020View ASX Announcement
Updated Capital StructureOctober 2020View ASX Announcement
September 2020 Quarterly Activities Report and Appendix 4COctober 2020View ASX Announcement
Notice of Annual General Meeting Proxy FormOctober 2020View ASX Announcement
Securities Trading PolicyOctober 2020View ASX Announcement
Updated Capital StructureOctober 2020View ASX Announcement
September 2020 Quarterly Activities Report and Appendix 4COctober 2020View ASX Announcement
Medibio Limited – Annual Report – 30 June 2020September 2020View ASX Announcement
Appendix 4G and Corporate Governance StatementSeptember 2020View ASX Announcement
FDA Strategy and Regulatory UpdateAugust 2020View ASX Announcement
Medibio granted US Patent for Monitoring Stress Conditions Using HeartrateAugust 2020View ASX Announcement
Appendix 2A Application for quotation of & securitiesAugust 2020View ASX Announcement
Appendix 4E Preliminary Final Report 30 June 2020August 2020View ASX Announcement
FDA Strategy & Regulatory UpdateAugust 2020View ASX Announcement
Medibio Announces Entitlement Issue ResultsJuly 2020View ASX Announcement
Appendix 2A Application for quotation of + securitiesJuly 2020View ASX Announcement
Appendix 3Y Change of Director’s Interest NoticeJuly 2020View ASX Announcement
June Quarterly Activities Report and Appendix 4CJuly 2020View ASX Announcement
Appendix 2A Application for quotation of +securitiesJune 2020View ASX Announcement
Appendix 3G Notification of issue, conversion or payment up of equity +securitiesJune 2020View ASX Announcement
MEB Raises $2m via Placement and Fully Underwritten Entitlement OfferJune 2020View ASX Announcement
Offer Document Entitlement IssueJune 2020View ASX Announcement
Non-Renounceable Entitlement Offer Cleansing Notice under Section 708AA(2)(F) of the Corporations Act 2001 (Cth)June 2020View ASX Announcement
Section 708A Cleansing NoticeJune 2020View ASX Announcement
Investor PresentationJune 2020View ASX Announcement
Notification to ineligible shareholders of Entitlement OfferJune 2020View ASX Announcement
Notification of pro-rata non-renounceable Entitlement IssueJune 2020View ASX Announcement
Notification to eligible shareholders of Entitlement OfferJune 2020View ASX Announcement
Section 708A Cleansing Notice and Appendix 2AJune 2020View ASX Announcement
Despatch of Offer Letter to Eligible ShareholdersJune 2020View ASX Announcement
Appendix 3G Notification of issue, conversion or payment up of equity +securitiesJune 2020View ASX Announcement
MEB Announces Extension to Entitlement OfferJune 2020View ASX Announcement
Medibio Settles Joint Venture DisputeJune 2020View ASX Announcement Announcement Summary
Medibio’s ilumen™ supporting the global workforce during COVID-19 health crisisApril 2020View ASX Announcement
Final Compass Pilot completed successfullyApril 2020View ASX Announcement
Capital Structure UpdateApril 2020View ASX Announcement
Medibio Submits FDA 510K Application to the FDA for its Sleep Staging Medical Software DeviceApril 2020View ASX Announcement
Quarterly Activities Report and Appendix 4CApril 2020View ASX Announcement
Executive Appointments at Medibio to Support Growth of ilumen™March 2020View ASX Announcement
FDA Strategy UpdateMarch 2020View ASX Announcement
Medibio Signs Memorandum of Understanding with DXC for ilumen™March 2020View ASX Announcement
Strategic Plan for FDA and CE Mark ApprovalFebruary 2020View ASX Announcement
Medibio Signs Annual Services Agreement with Stantec Australia for ilumen™February 2020View ASX Announcement
Appendix 4D and Half-Yearly Report for 31 December 2019February 2020View ASX Announcement
Changes to the BoardJanuary 2020View ASX Announcement
Final Director’s Interest NoticeJanuary 2020View ASX Announcement
Letter from the Managing DirectorJanuary 2020View ASX Announcement
Quarterly Operations Report and AppendixJanuary 2020View ASX Announcement
Document namedateLink
Report to Shareholders and Outlook for 2020December 2019View ASX Announcement
Appendix 3G: Notification of issue, conversion or payment up of equity +securitiesDecember 2019View ASX Announcement
Appendix 3Y: Change of Director’s Interest NoticeDecember 2019View ASX Announcement
Results of Annual General MeetingNovember 2019View ASX Announcement
Company UpdateNovember 2019View ASX Announcement
Final Directors Interest NoticeNovember 2019View ASX Announcement
Medibio Provides Updated Securities Trading PolicyOctober 2019View ASX Announcement
Medibio Successfully Completes First Pilot with Compass GroupOctober 2019View ASX Announcement
Medibio Notice of Annual General Meeting and Proxy FormOctober 2019View ASX Announcement
Notice of Ceasing to be a Substantial HolderOctober 2019View ASX Announcement
Medibio CEO to Participate on Panel at Garmin Digital Health Summit APACOctober 2019View ASX Announcement
Medibio Signs Agreement with PwC Australia for ilumen™October 2019View ASX Announcement
Quarterly Update and Appendix 4C 31 October 2019October 2019View ASX Announcement
Withdrawal of Notice of Initial Substantial ShareholdingSeptember 2019View ASX Announcement
Becoming A Substantial Holder 2 Sept 2019September 2019View ASX Announcement
Change in Substantial Holding 3 Sept 2019September 2019View ASX Announcement
Cleansing Notice 4 September 2019September 2019View ASX Announcement
Change of Directors Interest 4 Sept 2019September 2019View ASX Announcement
Initial Directors Interest 4 Sept 2019September 2019View ASX Announcement
Medibio Announces Results of Review of Partly Paid SharesSeptember 2019View ASX Announcement
Medibio Appendix 4G and Governance StatementSeptember 2019View ASX Announcement
Medibio 2019 Annual ReportSeptember 2019View ASX Announcement
Medibio Supplementary ProspectusAugust 2019View ASX Announcement
Medibio Results of August 2019 AGMAugust 2019View ASX Announcement
Medibio Appendix 3B 20 August 2019August 2019View ASX Announcement
Medibio Completes Oversubscribed Share Purchase PlanAugust 2019View ASX Announcement
Medibio ASX Information for New Quoted Option ClassAugust 2019View ASX Announcement
Medibio Appendix 3B 29 August 2019August 2019View ASX Announcement
Medibio Announces New Board Members and Establishes Growth & Advocacy Advisory BoardAugust 2019View ASX Announcement
Medibio Announces Fourth Pilot Agreement with Compass GroupAugust 2019View ASX Announcement
Medibio Appendix 4E Preliminary ReportAugust 2019View ASX Announcement
Medibio Becoming a Substantial Holder 30 Aug 2019August 2019View ASX Announcement
Medibio Appendix 3B 30 Aug 2019August 2019View ASX Announcement
Medibio Final Directors Notice 30 Aug 2019August 2019View ASX Announcement
Medibio Signs Global Organisation, Compass Group PLC, for the First of Two UK-based Pilots for ilumen™July 2019View ASX Announcement
Medibio Requests Trading Halt in Relation to Capital RaisingJuly 2019View ASX Announcement
Medibio Suspension from Official QuotationJuly 2019View ASX Announcement
Medibio Reinstatement to Official QuotationJuly 2019View ASX Announcement
Medibio Raises $4,020,000 By Way of a Placement and Fully Underwritten SPPJuly 2019View ASX Announcement
Medibio Signs Second Compass Group PLC Pilot for ilumen™July 2019View ASX Announcement
Medibio Notice of Extraordinary General Meeting, Explanatory Statement and Proxy FormJuly 2019View ASX Announcement
Medibio Notice of Change of Interest of Substantial HolderJuly 2019View ASX Announcement
Medibio Prospectus Offer of Options and Shares for SPPJuly 2019View ASX Announcement
Medibio Appendix 3BJuly 2019View ASX Announcement
Medibio Partners with Digital Corporate Wellness Solution Leader WellteQJuly 2019View ASX Announcement
Medibio Signs Compass Group Australia for Corporate Health Product ilumen™July 2019View ASX Announcement
Medibio Quarterly Operations Report and Appendix 4CJuly 2019View ASX Announcement
Appendix 3B New Issue AnnouncementJune 2019View ASX Announcement
Joint Venture DisputeJune 2019View ASX Announcement
Change of Directors NoticeJune 2019View ASX Announcement
Medibio Algorithm Validated in Study Published in Peer Reviewed JournalJune 2019View ASX Announcement
Medibio Provides Updated Investor DeckMay 2019View ASX Announcement
Medibio Results of General MeetingMay 2019View ASX Announcement
Medibio Response to ASX 4C QueryMay 2019View ASX Announcement
Medibio Provides Updated Investor Deck 27 May 2019May 2019View ASX Announcement
Medibio Provides Notice of General MeetingApril 2019View ASX Announcement
Medibio Announces Sponsored Research Agreement with HumanitasApril 2019View ASX Announcement
Medibio Announces Revised Regulatory and Commercialisation StrategyApril 2019View ASX Announcement
Medibio Provides Quarterly Message and Appendix 4CApril 2019View ASX Announcement
Medibio Corporate Health Product ilumen™ Successfully Completes First Commercial ProgramMarch 2019View ASX Announcement
Medibio Announces Entitlement Issue Results and Shortfall NotificationMarch 2019View ASX Announcement
Medibio Outsources Psychology Services in Support of Corporate Health Product ilumen™March 2019View ASX Announcement
Medibio Announces Completion of Entitlement IssueMarch 2019View ASX Announcement
Medibio Shareholder Update & OutlookMarch 2019View ASX Announcement
Medibio Provides Updated Investor PresentationMarch 2019View ASX Announcement
Medibio Extension of Entitlement OfferingFebruary 2019View ASX Announcement
Medibio Investor PresentationFebruary 2019View ASX Announcement
Medibio Announces Changes to Board of Directors and Appointment of ChairmanFebruary 2019View ASX Announcement
Medibio Announces Extension to Entitlement OfferFebruary 2019View ASX Announcement
Medibio Correction to Extension of Entitlement OfferFebruary 2019View ASX Announcement
Medibio Appendix 4D Half Year ReportFebruary 2019View ASX Announcement
Medibio Results of January 2019 General MeetingJanuary 2019View ASX Announcement
Medibio Cleansing Notice and Appendix 3BJanuary 2019View ASX Announcement
Medibio Quarterly Update & Cash FlowJanuary 2019View ASX Announcement
Document namedateLink
Medibio Requests Trading HaltDecember 2018View ASX Announcement
Medibio Converting Note & Non-Renounceable Entitlement OfferDecember 2018View ASX Announcement
Medibio Section 708AA(2)(F) Cleansing Statement and Appendix 3BDecember 2018View ASX Announcement
Medibio Updated Investor Presentation December 10, 2018December 2018View ASX Announcement
Medibio Notification of Pro-Rata Non-Renounceable Entitlement IssueDecember 2018View ASX Announcement
Medibio Letter to Shareholders Entitlement OfferDecember 2018View ASX Announcement
Medibio Letter to Ineligible Shareholders Entitlement OfferDecember 2018View ASX Announcement
Medibio Rights Issue Offer DocumentDecember 2018View ASX Announcement
Medibio Notice of General MeetingDecember 2018View ASX Announcement
Medibio Announces Changes to the Board of Directors and Cost Reduction PlansDecember 2018View ASX Announcement
Medibio Market UpdateNovember 2018View ASX Announcement
Medibio Appoints Global Healthcare & Medical Device Leader as CEO and Managing DirectorNovember 2018View ASX Announcement
Medibio Provides Update on FDA ProcessNovember 2018View ASX Announcement
Medibio Provides Chairman’s Address to ShareholdersNovember 2018View ASX Announcement
Medibio Announces Appointment of Joint Corporate SecretaryNovember 2018View ASX Announcement
Medibio Releases Results of Annual General MeetingNovember 2018View ASX Announcement
Medibio Signs Insurance Company AIA Australia Ltd (AIAA) For an Exclusive Pilot Program For ilumen™November 2018View ASX Announcement
Medibio Provides Updated Investor DeckNovember 2018View ASX Announcement
Notice Received Under Section 249D of the Corporations ActOctober 2018View ASX Announcement
Medibio Releases Corporate Health Product, ilumen™October 2018View ASX Announcement
Medibio Updates Company PresentationOctober 2018View ASX Announcement
Medibio Technology Honored with Two Presentations at Mayo Clinic Convergence Neuroscience 2018October 2018View ASX Announcement
Medibio Receives R&D Tax Incentive RefundOctober 2018View ASX Announcement
Medibio Notice of Annual General MeetingOctober 2018View ASX Announcement
Medibio Signs ilumen™ Corporate Contract with a Large Australian EmployerOctober 2018View ASX Announcement
Medibio Quarterly & Cash Flow ReportOctober 2018View ASX Announcement
Medibio Clinical Study Shows Over 20% Improvement to Current Diagnostic StandardSeptember 2018View ASX Announcement
Medibio Hosts Call to Discuss Clinical Validation StudySeptember 2018View ASX Announcement
Medibio Market UpdateSeptember 2018View ASX Announcement
Medibio Releases Appendix 4G & Corporate Governance StatementSeptember 2018View ASX Announcement
Medibio Releases Financial Report for the Year Ended 30 June 2018September 2018View ASX Announcement
Medibio Announces Executive Leadership ChangesSeptember 2018View ASX Announcement
Medibio announces change in senior managementAugust 2018View ASX Announcement
Medibio Submits FDA De Novo ApplicationJuly 2018View ASX Announcement
Medibio to announce fourth quarter FY18 resultsJuly 2018View ASX Announcement
Quarterly Update and Message from CEO of Medibio LimitedJuly 2018View ASX Announcement
Appointment and Resignation of Company Secretary And Change of Registered Office AddressJune 2018View Press Release PDF
Medibio provides updated Investor PresentationJune 2018View Press Release PDF
Medibio to Provide Corporate Health Investor PresentationJune 2018View Press Release PDF
Peer-reviewed Neurology Publication on Medibio ScienceJune 2018View ASX Announcement
Medibio Announces Global Launch – Corporate Mental Health For BusinessMay 2018View Press Release PDF
Medibio Receives CE CertificationMay 2018View Press Release PDF
Medibio Corporate Health contract signed with Australia’s 3rd largest private healthcare providerMay 2018View Press Release PDF
Medibio Launches Personal Mental Health Measurement App for Apple WatchMay 2018View Press Release PDF
Medibio Announces Next Tranche of Corporate Health ContractsMay 2018View Press Release PDF
Medibio Corporate Health Signs Global Contract with Jacobs EngineeringMay 2018View Press Release PDF
Medibio finalizes acquisition of Vital ConversationsApril 2018View Press Release PDF
Medibio Announces Scientific Advisory BoardApril 2018View Press Release PDF
Medibio to announce third Quarter FY18 update and cashflowApril 2018View ASX Announcement
Quarterly ASX Update and CashflowsApril 2018View ASX Announcement
Peter Carlisle Appointed as DirectorJanuary 2018View Press Release PDF
Medibio Investor Conference Call AnnouncementJanuary 2018Australia – 1st February
U.S. – January 31st
Document namedateLink
U.S. Department of Veterans Affairs White River Junction Medical Center Joins Medibio Depression Diagnostic Confirmatory Study to Support FDA ClearanceDecember 2017View ASX Announcement
Mayo Clinic to begin Prospective Clinical Study with Medibio Technology for Expanded Market OpportunitiesDecember 2017View ASX Announcement
Medibio Annual General Meeting MaterialsNovember 2017View ASX Announcement Watch Videos
Medibio Enters Into an Agreement with Otsuka Pharmaceutical Development & Commercialization, Inc.October 2017View ASX Announcement
Medibio’s Depression Diagnostic Ready for FDA Confirmatory Study. (Aug 2 2017)August 2017View ASX Announcement
Medibio Initiates Enrollment for Its Depression Diagnostic Confirmatory Study to Support FDA Clearance (Aug 21 2017)August 2017View ASX Announcement
The Honourable Patrick Kennedy Appointed to Medibio Board of Directors (2 Jul 2017)July 2017View ASX Announcement
Adam Darkins, Telehealth icon appointed to Medibio board (19 Jul 2017).July 2017View ASX Announcement
Michael Phelps, World Champion Athlete and Mental Health Advocate, Appointed to Medibio Board of Directors (5 Jun 2017)June 2017View ASX Announcement
Medibio Limited Begins Trading on OTCQB Under Ticker Symbol MDBIF (5 Jun 2017)June 2017View ASX Announcement
Medibio Investor Deck Update (5 Jun 2017)June 2017View ASX Announcement
Independent researchers present first data validating Medibio’s technology at the prestigious “Sleep 2017” (8 Jun 2017)June 2017View ASX Announcement
Scientific breakthrough on objective diagnosis of PTSD (27 Jun 2017)June 2017View ASX Announcement
Medibio signs strategic joint Development Agreement with Mayo Clinic.May 2017View ASX Announcement
Medibio appoints experienced US based med-tech CFO (21 Apr 2017)April 2017View ASX Announcement
Change of Director’s Interest Notice (20 Apr 2017)April 2017View ASX Announcement
MEB enters fully funded Paediatric mental illness diagnostic (10 Apr 2017)April 2017View ASX Announcement
Conversion of Options to Partly Paid shares (5 Apr 2017)April 2017View ASX Announcement
Change of Director’s Interest Notice (5 Apr 2017)April 2017View ASX Announcement
Investor Presentation Deck (20 Mar 2017)March 2017View ASX Announcement
Appointment of Non Executive Director & Advisory Board Chang (1 Feb 2017)February 2017View ASX Announcement
Medibio Appoints US and med-tech veteran as CEO and Managing Director (16 Feb 2017)February 2017View ASX Announcement
Partnership with leading US University on Post Traumatic Stress Disorder (25 Jan 2017)January 2017View ASX Announcement
Early Repayment of Convertible Note (30 Jan 2017)January 2017View ASX Announcement
Quarterly Update – Q4 2016 (31 Jan 2017)January 2017View ASX Announcement
Document namedateLink
APP 3B (5 Dec 2016)December 2016View ASX Announcement
Medibio’s Depression Diagnostic demonstrated excellent performance in the pilot phase of its US Validation Study (21 Dec 2016)December 2016View ASX Announcement
Medibio’s Depression Diagnostic demonstrates excellent performance in the pilot phase of its US Validation Study (21 Dec 2016)December 2016View ASX Announcement
App 3B (3 Nov 2016)November 2016View ASX Announcement
University of Ottawa Depression Study improves accuracy rate to an outstanding 86% in a far larger sample. (Nov 16)November 2016View ASX Announcement
Capital raising of $13.5 million to accelerate growth (Nov 16)November 2016View ASX Announcement
Medibio Limited announces that Dr James Campbell has resigned as a Non-Executive Director of MedibioNovember 2016View ASX Announcement
Medibio AGM Presentation (Nov 29)November 2016View ASX Announcement
App 3B (7 Oct 2016)October 2016View ASX Announcement
Funding Update (10 Oct 16)October 2016View ASX Announcement
MEB Annual 2016 (10 Oct 2016)October 2016View ASX Announcement
Partners with HBF and Vital Conversation (11 Oct 2016)October 2016View ASX Announcement
MEB R & D Tax Incentive RefundOctober 2016View ASX Announcement
Notice of Annual General Meeting (28 Oct 2016)October 2016View ASX Announcement
Medibio Shareholder Newsletter (28 Oct 2016)October 2016View ASX Announcement
App 3B (28 Oct 2016)October 2016View ASX Announcement
Quarterly report (31 Oct 2016)October 2016View ASX Announcement
Quarterly Cash Flow Report (30 Oct 2016)October 2016View ASX Announcement
MEB and Monash establish groundbreaking partnership on innovation for sleep and mental health solution (September 2016)September 2016View ASX Announcement
Director’s Resignation (30 Sep 2016)September 2016View ASX Announcement
Trading Halt Request (5 Aug 2016)August 2016View ASX Announcement
Depression Validation Results (August 2016)August 2016View ASX Announcement
BMC Collaboration (17 Aug 2016)August 2016View ASX Announcement
Investor Presentation (23 Aug 2016)August 2016View ASX Announcement
Preliminary Final Report (31 Aug 2016)August 2016View ASX Announcement
Quarterly Report (31 Jul 2016)July 2016View ASX Announcement
Medibio’s Advanced Analytics Cloud Solution Breaks (24 June 2016)June 2016View ASX Announcement
US Investor Presentation (28 June 2016)June 2016View ASX Announcement
App 3B (30 June 2016)June 2016View ASX Announcement
First Commercial Pilot (30 May 2016)May 2016View ASX Announcement
Investor Presentation April 2016 (4 April 2016)April 2016View ASX Announcement
Medibio Acquires Key IP (19 April 2016)April 2016View ASX Announcement
Shareholder Newsletter Issue 3 – (21 April 2016)April 2016View ASX Announcement
708 Disclosure (29 April 2016)April 2016View ASX Announcement
Appendix 3B New issue announcement (29 April 2016)April 2016View ASX Announcement
Quarterly Report – March 2016 (30 April 2016)April 2016View ASX Announcement
Apple Watch and Fitbit intergration (8 March 2016)March 2016View ASX Announcement
Four leading US Institutions provide Medibio 10000 data sets (14 March 2016)March 2016View ASX Announcement
BioMelbourne Conference on Wireless and Wearable Technology (17 March 2016)March 2016View ASX Announcement
Partnership to evaluate wearables (8 Feb 2016)February 2016View ASX Announcement
First Wellness Channel Partner commercial pilot (16 Feb 2016)February 2016View ASX Announcement
MEB Half Yearly Report and Accounts to 31 December 2015 (28 Feb 2016)February 2016View ASX Announcement
MEB Receipt of R & D Tax Incentive Refund (14 Jan 2016)January 2016View ASX Announcement
MEB ASX Rlease Re-Frank Prendergast(27 Jan 2016)January 2016View ASX Announcement
MEB Initial Directors Interest (27 Jan 2016)January 2016View ASX Announcement
MEB Dec Quarterly Report (31 Jan 2016)January 2016View ASX Announcement
MEB Agreement with Wellnovation (31 Jan 2015)January 2016View ASX Announcement
MEB Appendix 3B Amendment and re-lodgement (31 Jan 2016)January 2016View ASX Announcement
Document namedateLink
MEB and WellNovation MOU takes stress diagnostic to Saudi Arabia and Gulf Cooperation CouncilDecember 2015View ASX Announcement
MEB Quarterly Report for the period ending (30 Sep 2015)November 2015View ASX Announcement
MEB’s Signs First Multinational Client (6 Nov 2015)November 2015View ASX Announcement
MEB Foster Research Report (10 Nov 2015)November 2015View ASX Announcement
MEB ASX Investor Series Presentation (17 Nov 2015)November 2015View ASX Announcement
MEB Final JHU Release-IRB (ASX Release) (24 Nov 2015)November 2015View ASX Announcement
MEB Corporate Wellness Partner Program Commences (26 Nov 2015)November 2015View ASX Announcement
MEB Key to Disclosures Corporate Governance Council Principles and RecommendationsOctober 2015View ASX Announcement
MEB collaborates with University of Ottawa on research (12 Oct 2015)October 2015View ASX Announcement
MEB Annual Report 2015 (28 Oct 2015)October 2015View ASX Announcement
MEB Notice of Annual General Meeting (30 Oct 2015)October 2015View ASX Announcement
MEB Capital raising of $3.1 million to accelerate growth (2 September 2015)September 2015View ASX Announcement
MEB launches Corporate Wellness Partner Program for its Corporate Stress Product (25 September 2015)September 2015View ASX Announcement
MEB June 2015 Quarter Operations Report (4 Aug 2015)August 2015View ASX Announcement
MEB US Broker Report (17 Aug 2015)August 2015View ASX Announcement
MEB US Update (17 Aug 2015)August 2015View ASX Announcement
MEB Completes Development of Corporate Stress Product (21 Aug 2015)August 2015View ASX Announcement
MEB First Commercial Deal (27 August 2015)August 2015View ASX Announcement
MEB Investor Presentation (August 2015)August 2015View ASX Announcement
MEB Stress Patent (2 July 2015)July 2015View ASX Announcement
MEB Medical Patent (15 July 2015)July 2015View ASX Announcement
MEB Investor Presentation (July 2015)July 2015View ASX Announcement
Medibio Ltd processes first participant in UNSW depression test validation study (11 May 2015)May 2015View ASX Announcement
March Quarterly Activities Report (13 May 2015)May 2015View ASX Announcement
MEB Preventice MOU Release (28 May 2015)May 2015View ASX Announcement
Medibio Press Article (May 2015)May 2015View ASX Announcement
Medibio Investor Presentation (April 2015)April 2015View ASX Announcement
Completion of Restructure (2 April 2015)April 2015View ASX Announcement
Distinguished Clinician Dr Frank Prendergast joins MEB (12 April 2015)April 2015View ASX Announcement
U.S. Patent (21 April 2015)April 2015View ASX Announcement
Investor Presentation April 2016 (4 April 2016)April 2015View ASX Announcement
Medibio Acquires Key IP (19 April 2016)April 2015View ASX Announcement
Shareholder Newsletter Issue 3 – (21 April 2016)April 2015View ASX Announcement
708 Disclosure (29 April 2016)April 2015View ASX Announcement
Appendix 3B New issue announcement (29 April 2016)April 2015View ASX Announcement
Quarterly Report – March 2016 (30 April 2016)April 2015View ASX Announcement
Broker Research (22 April 2015)April 2015View ASX Announcement
Medibo Investor NewsletterMarch 2015View ASX Announcement
Results of General Meeting (6 March 2015)March 2015View ASX Announcement
General Meeting Presentation (6 March 2015)March 2015View ASX Announcement
U.S. Depression market size (6 Feb 2015)February 2015View ASX Announcement
Medibio Limited Health Stage 1 ProgramFebruary 2015View ASX Announcement
Medibio Presentation Jan 2015(ASX Release)January 2015View ASX Announcement
Market Update restructure (Final)January 2015View ASX Announcement
Document namedateLink
MEB (JHU Release) Lodgement VersionDecember 2014View ASX Announcement
NAMSA US TrialsDecember 2014View ASX Announcement
BPO Share Issue Cleansing StatementNovember 2014View ASX Announcement
BPO Trading Halt Request correctionNovember 2014View ASX Announcement
BPO ASX Release Name ChangeNovember 2014View ASX Announcement
BPO ASX Release AGM ResultsNovember 2014View ASX Announcement
BPO Appendix 3B B Kay Taurus C Note Share Issue revisedNovember 2014View ASX Announcement
BPO ASX Release MJP Appointment approved for releaseNovember 2014View ASX Announcement
BPO ASX Release BDI StudyNovember 2014View ASX Announcement
BPO Baillieu Holst ResearchOctober 2014View ASX Announcement
Stephen Pearce, Fortescue Metals CFO, joins BPO as AdvisorJuly 2014View ASX Announcement
Final Director’s Interest NoticeJuly 2014View ASX Announcement
Change in Substantial HoldingJuly 2014View ASX Announcement
Initial Director’s Interest NoticeJuly 2014View ASX Announcement
Board AppointmentJuly 2014View ASX Announcement
Change of Director’s Interest NoticeJune 2014View ASX Announcement
BPO Responds to Explosive Demand for E-Health Consumer ProdJune 2014View ASX Announcement
Change in substantial HoldingJune 2014View ASX Announcement
Change of Director’s Interest NoticeJune 2014View ASX Announcement
Appendix 3BMay 2014View ASX Announcement
BioProspect Letter to ShareholdersMay 2014View ASX Announcement
Frontier Oil Corporation UpdateMay 2014View ASX Announcement
Appendix 3Z B CooperMay 2014View ASX Announcement
Appendix 4C March 2014April 2014View ASX Announcement
Appendix 3X V FayadApril 2014View ASX Announcement
Appendix 3X C SolitarioApril 2014View ASX Announcement
BioProspect Board Changes & Executive AppointmentsApril 2014View ASX Announcement
BioProspect Acquires Diagnostic Tool for Mental IllnessApril 2014View ASX Announcement
Successful Completion of Technical Due DiligenceMarch 2014View ASX Announcement
Appendix 4DMarch 2014View ASX Announcement
Frontier Oil Corporation UpdateFebruary 2014View ASX Announcement
Results of General MeetingFebruary 2014View ASX Announcement
Invatec Heartlink Transaction UpdateFebruary 2014View ASX Announcement
Appendix 3BJanuary 2014View ASX Announcement
Issue of Convertible NotesJanuary 2014View ASX Announcement
Change of Interest of Substantial HolderJanuary 2014View ASX Announcement
Appendix 4CJanuary 2014View ASX Announcement
Notice of MeetingJanuary 2014View ASX Announcement
Document namedateLink
Expiry of OptionsDecember 2013View ASX Announcement
Investor Presentation InvatecDecember 2013View ASX Announcement
Expiry of OptionsDecember 2013View ASX Announcement
Cleansing StatementDecember 2013View ASX Announcement
Appendix 3BDecember 2013View ASX Announcement
Options to acquire Depression Diagnostic ProjectDecember 2013View ASX Announcement